/assets/production/practices/7d6882f660ea7189b4e99604409a4baac5316a60/images/2862843.jpeg)
Mediastinal Mass services offered in Miami, FL
Mediastinal masses can represent a wide range of benign and malignant conditions and may affect the heart, lungs, airway, esophagus, blood vessels, and other vital structures within the chest. At the Institute for Thoracic Surgery in Miami, Florida, Mark R. Dylewski, M.D., provides specialized surgical evaluation and treatment for patients with mediastinal masses, including tumors and other complex disorders involving the thymus, lymph nodes, nerves, and surrounding mediastinal structures. His approach incorporates advanced imaging, multidisciplinary evaluation, and minimally invasive surgical techniques whenever appropriate, with treatment tailored to the specific diagnosis, location, size, and extent of the mass. When surgery is indicated, Dr. Dylewski utilizes modern thoracic surgical approaches, including robotic-assisted and video-assisted thoracic surgery (VATS), as well as open surgery when necessary, with the goal of achieving safe and complete treatment while minimizing surgical trauma.
Mediastinal masses represent a diverse group of benign and malignant lesions arising from the thymus, lymphatic system, nerves, germ cells, thyroid or parathyroid tissue, esophagus, tracheobronchial tree, vascular structures, and other mediastinal tissues. Traditionally, the mediastinum has been divided into four compartments—superior, anterior, middle, and posterior—although the contemporary CT-based classification endorsed by the International Thymic Malignancy Interest Group (ITMIG) uses three compartments: prevascular, visceral, and paravertebral. In the traditional four-compartment model, the superior mediastinum contains the thymic remnants, great vessels, trachea, esophagus, lymphatic structures, and nerves and may harbor thyroid or parathyroid lesions, lymphadenopathy, lymphoma, metastatic disease, vascular abnormalities, and other masses. The anterior mediastinum contains primarily thymic tissue, fat, and lymph nodes and is classically associated with thymic tumors and cysts, lymphoma, germ-cell tumors, and thyroid or parathyroid lesions. The middle mediastinum contains the heart, pericardium, great vessels, trachea, main bronchi, and lymph nodes and may give rise to bronchogenic or pericardial cysts, vascular lesions, lymphadenopathy, and lesions involving the airway, esophagus, or cardiovascular structures. The posterior mediastinum contains the esophagus, thoracic aorta, sympathetic chain, and other neural structures and is particularly associated with neurogenic tumors, including schwannomas and neurofibromas, as well as esophageal, vascular, osseous, and paravertebral abnormalities. The etiology of a mediastinal mass may therefore be neoplastic, congenital, infectious, inflammatory, vascular, or traumatic, with the differential diagnosis influenced substantially by the patient's age, clinical history, anatomic location, and imaging characteristics. Risk factors vary according to the underlying disease and may include increasing age, tobacco exposure, prior malignancy, immunosuppression, previous radiation therapy, autoimmune disease, and conditions associated with chronic infection or inflammation. Patients may be asymptomatic, with a mass discovered incidentally on chest radiography or CT, or may present with chest pain or pressure, cough, dyspnea, wheezing, dysphagia, hoarseness, recurrent respiratory infections, or symptoms related to airway, esophageal, vascular, or nerve compression. Constitutional symptoms such as fever, night sweats, fatigue, and unexplained weight loss may suggest lymphoma, infection, or another systemic process. Accurate localization of the mass, followed by characterization with contrast-enhanced CT and, when appropriate, MRI, laboratory evaluation, PET/CT, or tissue diagnosis, is essential for establishing the etiology and guiding multidisciplinary treatment.
Mediastinal Mass Q&A
Evaluation and Treatment of Mediastinal Masses
The evaluation of a mediastinal mass begins with a careful history and physical examination, followed by cross-sectional imaging to accurately localize the lesion, characterize its tissue composition, and determine its relationship to adjacent structures. Although the traditional four-compartment system divides the mediastinum into superior, anterior, middle, and posterior compartments, contemporary imaging commonly uses the ITMIG three-compartment classification of prevascular, visceral, and paravertebral compartments. Localization is important because it substantially narrows the differential diagnosis and helps determine the safest approach for tissue diagnosis and treatment. Contrast-enhanced CT of the chest is generally the principal initial diagnostic study because it defines the size, margins, density, enhancement pattern, calcification, fat or fluid content, lymphadenopathy, invasion of adjacent structures, and relationship to major vessels, airway, esophagus, and heart. MRI provides complementary information, particularly for differentiating cystic from solid lesions, identifying fat, characterizing thymic abnormalities, and evaluating invasion of vascular, neural, cardiac, or other soft-tissue structures.
The laboratory evaluation is directed by the suspected diagnosis and may include a complete blood count, metabolic studies, inflammatory markers, thyroid studies, and serum tumor markers such as alpha-fetoprotein (AFP) and beta-hCG when a germ-cell tumor is suspected. Additional disease-specific testing may be appropriate, such as evaluation for autoimmune disorders associated with thymic disease. FDG-PET/CT is not required for every mediastinal mass but can be particularly useful for staging lymphoma and other aggressive malignancies, assessing suspected metastatic disease, evaluating treatment response, and investigating recurrence. When tissue diagnosis is required, the method should be selected according to the location and suspected pathology and may include CT- or ultrasound-guided core-needle biopsy, endobronchial ultrasound-guided sampling, mediastinoscopy, VATS, robotic-assisted thoracoscopy, or open surgical biopsy. Importantly, not every mediastinal mass requires biopsy before treatment. A radiographically characteristic, localized lesion—particularly a potentially resectable thymic tumor—may appropriately proceed directly to surgical resection when complete removal is considered feasible. Conversely, biopsy is generally important when lymphoma, metastatic disease, a locally advanced or unresectable malignancy, or another tumor requiring systemic or neoadjuvant therapy is suspected.
Treatment
Treatment is determined by the etiology, compartment, histology, stage, symptoms, resectability, and relationship of the mass to surrounding structures. Benign mediastinal masses that are small, asymptomatic, and have characteristic imaging findings may be managed with observation and interval CT or MRI, particularly benign thymic cysts, thymic hyperplasia, and selected congenital cysts. Symptomatic, enlarging, uncertain, or potentially compressive benign lesions are often treated with surgical excision, both to relieve symptoms and to establish a definitive diagnosis. Depending on location and anatomy, resection may be performed through VATS, robotic-assisted thoracic surgery, cervical, supraclavicular, or open approaches, with the least invasive approach selected when complete and safe resection can be achieved. Current guidance specifically emphasizes avoiding nontherapeutic surgery when imaging strongly supports a benign asymptomatic lesion.
For malignant mediastinal masses, treatment should generally be coordinated through a multidisciplinary thoracic oncology team and may incorporate surgery, chemotherapy, immunotherapy, radiation therapy, or combinations of these modalities. Resectable thymic tumors are primarily treated with complete surgical resection, often including thymectomy and removal of surrounding perithymic tissue; minimally invasive VATS or robotic approaches can be considered in appropriately selected early-stage tumors. More locally advanced thymic malignancies may require induction chemotherapy followed by surgery when a complete resection becomes feasible, while unresectable or metastatic disease may require systemic therapy and/or definitive radiation. Lymphoma, in contrast, is generally treated primarily with systemic chemotherapy, immunotherapy, and/or radiation rather than surgical resection of the mediastinal mass. Germ-cell tumors similarly require histology-specific systemic treatment, with surgery playing a role in selected residual or resectable disease. Other malignant lesions, including metastatic tumors, neurogenic malignancies, sarcomas, and thymic carcinoma, require individualized multimodality treatment based on tumor biology, stage, and resectability. Thus, the fundamental goals of evaluation are to establish the anatomic origin and biologic nature of the mass, obtain tissue when necessary, accurately stage malignant disease, and select the least invasive treatment capable of achieving durable disease control or complete resection.